Key result
Oral captopril reduces cerebrospinal fluid ACE activity by ~60%, showing blood-brain barrier penetration.
Why the study?
The extent to which acute oral captopril inhibits ACE activity in human cerebrospinal fluid and penetrates the blood/brain barrier was unclear.
Does acute oral captopril inhibit ACE activity in human cerebrospinal fluid?
Population
Humans
Comparison
Acute oral dose (75 mg) of captopril vs baseline
Design
Other study design
Authors
Loading...
May indicate central ACE effects of oral captopril; leaves open clinical relevance pending prospective human trials.
Does acute oral captopril inhibit ACE activity in human cerebrospinal fluid?
Effect estimate: approx 60% decrease
Acute oral captopril penetrates the blood-brain barrier to inhibit ACE activity in human cerebrospinal fluid, suggesting a potential central mechanism for its antihypertensive effects.
Geppetti et al. (1987) studied this question. Captopril was evaluated on Angiotensin converting enzyme (ACE) activity in cerebrospinal fluid (approx 60% decrease). An acute 75 mg oral dose of captopril decreased angiotensin converting enzyme activity in human cerebrospinal fluid by approximately 60%, suggesting penetration of the blood-brain barrier.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: